

19 December 2025

Transaction by Person Discharging Managerial Responsibilities and Person Closely Associated

AstraZeneca PLC (the Company) announces that, on 17 December 2025, it was notified by Philip Broadley, Non-Executive Director, that on 17 December 2025, Mr Broadley gifted 5,735 ordinary shares of 0.25 each in the Company, for nil consideration, to his spouse, who is a person closely associated (PCA) to Mr Broadley.

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Philip Broadley				
2	Reason for the notification					
a)	Position/status	Non-Executive Director and PDMR				
b)	Initial notification /Amendment	Initial notification				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	AstraZeneca PLC				
b)	LEI	PY6ZZQWO2IZFZC3IOL08				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US 0.25 each in AstraZeneca PLC GB0009895292				
b)	Nature of the transaction	Gift of shares for nil consideration				
c)	Price(s) and volume(s)	<table border="1"><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>0</td><td>5,735</td></tr></table>	Price(s)	Volume(s)	0	5,735
Price(s)	Volume(s)					
0	5,735					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	17 December 2025				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Gillian Broadley
2	Reason for the notification	
a)	Position/status	Person Closely Associated (PCA) to Philip Broadley (PDMR)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US 0.25 each in AstraZeneca PLC GB0009895292				
b)	Nature of the transaction	Receipt of gift of shares for nil consideration				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>0</td> <td>5,735</td> </tr> </table>	Price(s)	Volume(s)	0	5,735
Price(s)	Volume(s)					
0	5,735					
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction				
e)	Date of the transaction	17 December 2025				
f)	Place of the transaction	Outside a trading venue				

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on social media [@AstraZeneca](https://www.twitter.com/AstraZeneca).

Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

Matthew Bowden
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHUWOURVSUUUAUA